ProMIS Neurosciences, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PMN research report →
Range $19 – $33
Price Chart
About the company
ProMIS Neurosciences, Inc. is a Canadian biotechnology firm dedicated to creating targeted therapeutic solutions for debilitating neurodegenerative conditions such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company leverages a unique computational discovery platform, utilizing its ProMIS and Collective Coordinates algorithms, to identify novel, disease-specific targets – known as epitopes – located on the surface of misfolded proteins.
- CEO
- Neil K. Warma
- IPO
- 2007
- Employees
- 11
- HQ
- Toronto, ON, CA
Get TickerSpark's AI analysis on PMN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $19.50M
- P/E
- -0.85
- PEG
- 0.00
- P/S
- 0.00
- P/B
- 2.76
- EV/EBITDA
- 0.80
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -143.09%
- ROIC
- -87.79%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-33,362,813+0.0%
- Op Income
- $-40,167,308
- Net Income
- $-39,719,147-1529.3%
- EPS
- $-22.61-922.2%
- OCF Growth
- -3.4%
- FCF Growth
- -3.4%
- 52W High
- $27.40
- 52W Low
- $6.27
- 50D MA
- $12.97
- 200D MA
- $12.20
- Beta
- -0.22
- RSI (14)
- 57
- Avg Volume
- 83.39K
No earnings-call transcripts are available for PMN yet.
- Free Float
- 64.1%
- Shares Outstanding
- 1.31M
- Float Shares
- 838.22K
of shares held by institutions
9 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Janus Henderson Group PLC | 1.29M | ▲ 1.29M |
| Allostery Investments LP | 155.72K | ▼ 77.98K |
| Graypoint LLC | 52.83K | ▲ 52.83K |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 5, 26 | Kaplan Johanne | buy | 2,280 |
| May 20, 26 | WYMAN WILLIAM W | other | 11,000 |
| May 20, 26 | WYMAN WILLIAM W | other | 5,500 |
| May 20, 26 | Williams Eugene | other | 11,000 |
| May 20, 26 | Williams Eugene | other | 5,500 |
| May 20, 26 | Warma Neil K | other | 160,000 |
| May 20, 26 | Shafmaster Madge K. | other | 11,000 |
| May 20, 26 | Shafmaster Madge K. | other | 5,500 |
| May 20, 26 | Cashman Neil | other | 50,000 |
| May 20, 26 | Milbury Max A. | other | 18,167 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our PMN coverage
Recent articles, reports, and earnings notes.
No research on PMN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PMN report →Promis Neurosciences Q2 Earnings Call Highlights
marketbeat.com · Aug 13
ProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate Highlights
globenewswire.com · Aug 13
Vertex Pharmaceuticals Inc (VRTX) (Q2 2026) Earnings Call Highlights: Revenue Surges 12% to $3.3 Billion, Driven by CF Portfolio and New Product Momentum
gurufocus.com · Aug 4
ProMIS Neurosciences to Report Second Quarter 2026 Financial Results and Business Update on August 13, 2026
globenewswire.com · Aug 3
ProMIS Neurosciences to Report Second Quarter 2026 Financial Results and Business Update on August 13, 2026
globenewswire.com · Aug 3
Promis Reports No ARIA-E in PMN310 Alzheimer's Trial Interim Data
marketbeat.com · Jul 28
Small-Cap ProMIS Neurosciences Says Lead Drug Shows Encouraging Action in Early Alzheimer's Study
benzinga.com · Jul 28
ProMIS Neurosciences Reports Positive Blinded Six-Month Interim Safety and Biomarker Data for PMN310 in the PRECISE-AD Phase 1b Alzheimer’s Disease Trial
globenewswire.com · Jul 28
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.